Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.70 ▼ -0.04
(-5.57%)
MKT CAP: $70.3M • VOL: 557.8K
52W L $1 52W H $2
ROARABLE / RQD
D- • 43/100
PIOTROSKI
2 / 9
CGTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$47.8M | -$54.0M | -$50.7M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$23.5M | -$34.0M | -$25.8M |
| EBITDA (Normalized) | — | -$54.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$24.6M | -$28.5M | -$16.0M |
| Capital Expenditures (CapEx) | — | $4.0K | — |
| Free Cash Flow (FCF) | -$24.6M | -$28.5M | -$16.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $36.8M | $25.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $34.3M | $18.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CGTX.